Rafferty Asset Management
EWTX icon

Rafferty Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Rafferty Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,849
Closed -$244K – 1091
2025
Q4 		$244K Buy
+9,849
New +$198K ﹤0.01% 1036
2025
Q2 		– Sell
-12,217
Closed -$269K – 1086
2025
Q1 		$269K Buy
12,217
+311
+3% +$8.16K ﹤0.01% 983
2024
Q4 		$318K Sell
11,906
-1,338
-10% -$42.6K ﹤0.01% 1018
2024
Q3 		$353K Buy
+13,244
New +$263K ﹤0.01% 1009

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Rafferty Asset Management's EWTX Position: Q1 2026 in Review

Rafferty Asset Management sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 9,849 shares — an estimated $244K sold.

Rafferty Asset Management first reported a position in EWTX in Q3 2024 and held it in 4 quarters. The position peaked at $353K in Q3 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Rafferty Asset Management reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 9,849 Edgewise Therapeutics shares in Q1 2026, an estimated $244K.
  • Rafferty Asset Management first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 4 quarters.
  • Rafferty Asset Management's Edgewise Therapeutics position peaked at $353K in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.